Scott L. Burrows
Chief Financial Officer · Spyre Therapeutics, Inc.
- 2025
- Oct 3, 2026
- 10
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Scott L. Burrows files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Fairmount Funds Management LLC - $399.66M in SYRE purchases and sales in the last 12 months
- Cameron Turtle - $10.91M in SYRE purchases and sales in the last 12 months
- Michael Thomas Henderson - $7.95M in SYRE purchases and sales in the last 12 months
- Sheldon Sloan - $7.35M in SYRE purchases and sales in the last 12 months
- Heidy King-Jones - $5.11M in SYRE purchases and sales in the last 12 months
- Jeffrey W. Albers - $2.40M in SYRE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Scott L. Burrows?
Scott L. Burrows is a corporate insider, tracked as Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Scott L. Burrows submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Scott L. Burrows been buying or selling stock?
Recorded transactions: 0 open-market purchases and 27 open-market sales ($9.42M) across all tracked filings.
